GlassScriptPhysician profile
Aaron K Nada
NPI 1326080094
$1,072.17
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $216 · 2021: $302 · 2022: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $233.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $183.04 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $156.31 | 2019-2021 | |
| Amgen INC. | $141.96 | 2019-2022 | |
| Horizon Therapeutics Plc | $121.62 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $47.47 | 2021-2022 | |
| Akebia Therapeutics INC | $42.07 | 2019-2021 | |
| Amicus Therapeutics, INC. | $24.21 | 2019 | |
| Nxstage Medical, INC. | $22.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.92 | 2021 | |
| Calliditas Therapeutics US INC. | $17.92 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.86 | 2021 | |
| Glaxosmithkline, LLC. | $16.75 | 2021 | |
| Abbvie INC. | $15.15 | 2021 | |
| Mallinckrodt Enterprises LLC | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Nada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.